Aug 12, 2026 · 1h 17m
GLP-1 treatment works best beyond the scale
What We Got Wrong About GLP-1s (And What's Right) | Dr. Tyna Moore
As GLP-1 use expands, the episode examines how dosing, monitoring, nutrition, and strength training shape its benefits and risks.
- 1GLP-1 therapy should address metabolic dysfunction rather than serve as a standalone solution for weight loss.
- 2Individualized dosing may reduce side effects while protein, resistance training, and monitoring help preserve muscle and bone.
- 3Weight regain, vision concerns, gut health, and uncertain long-term effects make clinical oversight essential.
Don't miss
Moore reframes muscle loss during GLP-1 treatment as largely a preventable consequence of inadequate protein and resistance training, not an inherent drug effect.
The brief
Tina Moore and Mark Hyman revisit GLP-1 treatment through a metabolic-health lens, arguing that medication should complement nutrition, exercise, testing, and clinical support rather than replace them.
The conversation challenges the idea that GLP-1s inherently destroy muscle: inadequate protein and resistance training are presented as the larger threats during weight loss.
Moore makes the case for individualized, physiological dosing, including minimum-effective-dose strategies shaped by genetics, goals, metabolic status, side effects, and treatment response.
Potential benefits extend beyond weight loss, but the episode keeps uncertainty in view, covering immune and addiction-related effects alongside vision, gastrointestinal, gallbladder, and pancreatic concerns.
The practical prescription is broader than a drug: assess insulin and nutritional status, monitor muscle and bone, protect lower-body strength, and use reputable clinicians and supply chains.
Featuring
Zepbound
Ozempic
Gila monster
Function HealthListen to the full episode and explore every guest, topic, and moment on PodLume.